Arbutus to Participate in September Investor Conferences
September 06 2022 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop novel therapeutics that target specific viral
diseases, today announced that the Company will participate in the
following upcoming investor conferences taking place in New York:
H.C. Wainwright 24th Annual Global
Investment Conference (September 12-14, 2022)
- Company Presentation: Tuesday,
September 13th at 12:30 pm ET
- Presenter: William Collier,
President & Chief Executive Officer
Baird’s 2022 Global Healthcare
Conference (September 13-14, 2022)
- Fireside Chat: Wednesday, September
14th at 10:15 am ET
- Presenters: William Collier,
President & Chief Executive Officer; Dr. Gaston Picchio, Chief
Development Officer; Michael McElhaugh, Chief Business Officer; and
David Hastings, Chief Financial Officer
Live webcasts of the presentation and fireside
chat can be accessed through the Investors section of Arbutus'
website at www.arbutusbio.com. An archived replay of the
webcast will be available on the Arbutus website after the
event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. In HBV, we are
developing a RNAi therapeutic, oral capsid inhibitor, oral PD-L1
inhibitor, and oral RNA destabilizer that we intend to combine to
provide a functional cure for patients with chronic HBV by
suppressing viral replication, reducing surface antigen and
reawakening the immune system. We believe our lead compound,
AB-729, is the only RNAi therapeutic with evidence of immune
re-awakening. It is currently being evaluated in multiple phase 2
clinical trials. We also have an ongoing drug discovery and
development program directed to identifying novel, orally active
agents for treating coronavirus (including SARS-CoV-2). In
addition, we are exploring oncology applications for our internal
PD-L1 portfolio. For more information, visit
www.arbutusbio.com.Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comLisa M. CaperelliVice President, Investor
RelationsPhone: 215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024